Intelligence Feed event · Policy · 2026-10-19

    Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress

    Question

    Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress

    Direct answer

    Zentalis Pharmaceuticals presented interim overall survival results from the DENALI Part 1b trial of its lead WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer. The data were released in conjunction with the ESMO Congress 2026. The trial demonstrated strong biomarker stratification: patients exhibiting Cyclin E1 overexpression achieved a median overall survival of 15.8 months across 48 evaluable subjects, compared to 7.5 months in Cyclin E1-negative patients. The differentiation provides validation for prospective patient selection in registration studies.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress”, revision 1, evidence through 2026-10-19. https://marketontology.com/market-events/2026-10-19/zentalis-reports-15-8-month-median-os-for-azenosertib-at-esmo-congress-269cea

    POLICY
    Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress
    Zentalis Pharmaceuticals presented interim overall survival results from the DENALI Part 1b trial of its lead WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer. The data were released in conjunction with the ESMO Congress 2026. The trial demonstrated strong biomarker stratification: patients exhibiting Cyclin E1 overexpression achieved a median overall survival of 15.8 months across 48 evaluable subjects, compared to 7.5 months in Cyclin E1-negative patients. The differentiation provides validation for prospective patient selection in registration studies.
    ZNTLXBI
    Impact
    72
    OCT 19
    SIG
    85%
    ZNTLXBI
    Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress
    Zentalis Pharmaceuticals presented interim overall survival results from the DENALI Part 1b trial of its lead WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer. The data were released in conjunction with the ESMO Congress 2026. The trial demonstrated strong biomarker stratification: patients exhibiting Cyclin E1 overexpression achieved a median overall survival of 15.8 months across 48 evaluable subjects, compared to 7.5 months in Cyclin E1-negative patients. The differentiation provides validation for prospective patient selection in registration studies.
    → A 15.8-month vs 7.5-month median overall survival advantage derisks azenosertib's Phase 3 development, re-rating ZNTL clinical equity value.
    Impact
    Zentalis Pharmaceuticals presented interim overall survival results from the DENALI Part 1b trial of its lead WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer. The data were released in conjunction with the ESMO Congress 2026. The trial demonstrated strong biomarker stratification: patients exhibiting Cyclin E1 overexpression achieved a median overall survival of 15.8 months across 48 evaluable subjects, compared to 7.5 months in Cyclin E1-negative patients. The differentiation provides validation for prospective patient selection in registration studies.
    Affected
    ZNTLXBI
    Transmission
    A 15.8-month vs 7.5-month median overall survival advantage derisks azenosertib's Phase 3 development, re-rating ZNTL clinical equity value.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZNTLclinical derisking of lead asset pipeline via statistically superior overall survival readoutUpintradayESMO abstract confirmed 15.8-month median OS for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.
    XBIbiotech sentiment uplift on positive late-stage clinical oncology efficacy readoutsUp1-5dBroad small/mid-cap biotech index captures oncology pipeline valuation adjustments.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month